Trademark Search in Canada

STARLIT

View On IC.GC.CA

ADVERTISED

on 27 Dec 2024

Last Applicant/ Owned by

F. Hoffmann-La Roche AG

Grenzacherstrasse 124CH-4070 Basel

Serial Number

2157393 filed on 5^th Nov 2021

Registration Number

TMA1278731 registered on 27^th Dec 2024

Registration expiry Date

5^th Nov 2031

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 2600, 160 ELGIN STREETOTTAWA

ONTARIO

K1P1C3

STARLIT

Trademark usage description

augmented reality and virtual reality medical software for developing and assessing functional vision endpoints for clinical trials of emerging therap Read More

Classification Information

Class [009]
Augmented reality and virtual reality medical software for developing and assessing functional vision endpoints for clinical trials of emerging therapies and pharmaceuticals in the field of ophthalmology; software for facilitating medical and scientific research including in a virtual reality environment, namely, conducting clinical and preclinical trials and studies in the fields of ophthalmology and pharmaceutical development; software that incorporates augmented reality and virtual reality to assess and predict the clinical efficacy of emerging therapies and pharmaceuticals in the field of ophthalmology; software for use in the field of ophthalmology for evaluating the effectiveness of emerging therapies and pharmaceuticals in the field of ophthalmology; software using artificial intelligence for use in pharmaceutical drug development, evaluating emerging therapies and pharmaceuticals in the field of ophthalmology, and conducting clinical trials in the field of ophthalmology and pharmaceutical development.

Classification kind code

Class [010]
Ophthalmological medical devices using augmented reality and virtual reality for use in evaluating, diagnosing and treating ophthalmologic diseases and disorders, and for use in conducting clinical and preclinical trials and studies in the fields of ophthalmology and pharmaceutical development; Ophthalmological device, namely, a head mounted display for evaluating, diagnosing and treating ophthalmological diseases and disorders, and structural parts thereof.

Classification kind code

Class [042]
Software as a service (SAAS) services featuring augmented reality and virtual reality medical software for developing and assessing functional vision endpoints for clinical trials of emerging therapies and pharmaceuticals in the field of ophthalmology; software as a service (SAAS) services featuring software for facilitating medical and scientific research including in a virtual reality environment, namely, conducting clinical and preclinical trials and studies in the fields of ophthalmology and pharmaceutical development; software as a service (SAAS) services featuring software that incorporates augmented reality and virtual reality to assess and predict the clinical efficacy of emerging therapies and pharmaceuticals in the field of ophthalmology; software as a service (SAAS) services featuring software for use in the field of ophthalmology for evaluating the effectiveness of emerging therapies and pharmaceuticals in the field of ophthalmology; software as a service (SAAS) services featuring software using artificial intelligence for use in pharmaceutical drug development, evaluating emerging therapies and pharmaceuticals in the field of ophthalmology, and conducting clinical trials in the field of ophthalmology and pharmaceutical development; platform as a service (SAAS) services featuring augmented reality and virtual reality medical software for developing and assessing functional vision endpoints for clinical trials of emerging therapies and pharmaceuticals in the field of ophthalmology; platform as a service (PaaS) featuring computer software platforms for facilitating medical and scientific research including in a virtual reality environment, namely, conducting clinical and preclinical trials and studies in the fields of ophthalmology and pharmaceutical development; platform as a service (PaaS) featuring computer software platforms that incorporates augmented reality and virtual reality to assess and predict the clinical efficacy of emerging therapies and pharmaceuticals in the field of ophthalmology; platform as a service (PaaS) featuring computer software platforms for use in the field of ophthalmology for evaluating the effectiveness of emerging therapies and pharmaceuticals in the field of ophthalmology; platform as a service (PaaS) featuring computer software platforms using artificial intelligence for use in pharmaceutical drug development, evaluating emerging therapies and pharmaceuticals in the field of ophthalmology, and conducting clinical trials in the field of ophthalmology and pharmaceutical development; cloud-based augmented/virtual reality platform for developing and assessing functional vision endpoints for clinical trials of emerging therapies and pharmaceuticals in the field of ophthalmology; cloud-based augmented/virtual reality platform for facilitating medical and scientific research including in a virtual reality environment, namely, conducting clinical and preclinical trials and studies in the fields of ophthalmology and pharmaceutical development; cloud-based augmented/virtual reality platform that incorporates augmented reality and virtual reality to assess and predict the clinical efficacy of emerging therapies and pharmaceuticals in the field of ophthalmology; cloud-based augmented/virtual reality platform for use in the field of ophthalmology for evaluating the effectiveness of emerging therapies and pharmaceuticals in the field of ophthalmology; cloud-based augmented/virtual reality platform using artificial intelligence for use in pharmaceutical drug development, evaluating emerging therapies and pharmaceuticals in the field of ophthalmology, and conducting clinical trials in the field of ophthalmology and pharmaceutical development; providing temporary use of online non-downloadable augmented reality and virtual reality medical software for developing and assessing functional vision endpoints for clinical trials of emerging therapies and pharmaceuticals in the field of ophthalmology; providing temporary use of online non-downloadable medical software for facilitating medical and scientific research including in a virtual reality environment, namely, conducting clinical and preclinical trials and studies in the fields of ophthalmology and pharmaceutical development; providing temporary use of online non-downloadable medical software that incorporates augmented reality and virtual reality to assess and predict the clinical efficacy of emerging therapies and pharmaceuticals in the field of ophthalmology; providing temporary use of online non-downloadable medical software for use in the field of ophthalmology for evaluating the effectiveness of emerging therapies and pharmaceuticals in the field of ophthalmology; providing temporary use of online non-downloadable medical software using artificial intelligence for use in pharmaceutical drug development, evaluating emerging therapies and pharmaceuticals in the field of ophthalmology, and conducting clinical trials in the field of ophthalmology and pharmaceutical development; providing non downloadable augmented reality and virtual reality medical software for developing and assessing functional vision endpoints for clinical trials of emerging therapies and pharmaceuticals in the field of ophthalmology; providing non-downloadable virtual reality software for facilitating medical and scientific research including in a virtual reality environment, namely, conducting clinical and preclinical trials and studies in the fields of ophthalmology and pharmaceutical development; providing non-downloadable virtual reality software that incorporates augmented reality and virtual reality to assess and predict the clinical efficacy of emerging therapies and pharmaceuticals in the field of ophthalmology; providing non-downloadable virtual reality software for use in the field of ophthalmology for evaluating the effectiveness of emerging therapies and pharmaceuticals in the field of ophthalmology; providing non-downloadable virtual reality software using artificial intelligence for use in pharmaceutical drug development, evaluating emerging therapies and pharmaceuticals in the field of ophthalmology, and conducting clinical trials in the field of ophthalmology and pharmaceutical development; clinical research in the field of developing and assessing endpoints for clinical trials of emerging therapies and pharmaceuticals in the field of ophthalmology; clinical studies on the efficacy of emerging therapies and pharmaceuticals in the field of ophthalmology; conducting research for others relating to emerging therapies, medical devices, and pharmaceuticals in the field of ophthalmology; providing medical and scientific research information in the field of pharmaceuticals; scientific research for medical purposes in the field of ophthalmology; pharmaceutical research and development; ophthalmic drug development; pharmaceutical product evaluation; design and development of computer hardware and software; medical and pharmacological research services.

Classification kind code

Mark Details

Serial Number

2157393

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 48 on 10^th May 2023	Agent Changed
Submitted for opposition 22 on 4^th May 2023	Search Recorded
Submitted for opposition 20 on 4^th May 2023	Examiner's First Report
Submitted for opposition 223 on 4^th May 2023	Total Provisional Refusal
Submitted for opposition 256 on 31^st Oct 2022	Notification of Possible Opposition Sent
Submitted for opposition 257 on 30^th Dec 2021	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 30^th Dec 2021	Formalized
Submitted for opposition 1 on 30^th Dec 2021	Created
Submitted for opposition 228 on 5^th Nov 2021	International Registration
Submitted for opposition 30 on 5^th Nov 2021	Filed